Heron Therapeutics Announces Executive & Director Compensation Changes
Ticker: HRTX · Form: 8-K · Filed: Oct 29, 2025 · CIK: 818033
Sentiment: neutral
Topics: executive-compensation, board-changes, corporate-governance, financial-statements
Related Tickers: HRTX
TL;DR
Heron Therapeutics (HRTX) filed an 8-K detailing exec/director comp changes and new board members.
AI Summary
Heron Therapeutics, Inc. announced on October 27, 2025, changes in its executive and director compensation arrangements. The filing details the election of new directors and the appointment of certain officers, alongside updates to compensatory arrangements for key personnel. This report also includes financial statements and exhibits relevant to these corporate governance and compensation matters.
Why It Matters
Changes in executive and director compensation can signal shifts in company strategy, performance expectations, or governance, potentially impacting investor confidence and future financial performance.
Risk Assessment
Risk Level: medium — Changes in executive and director compensation, board composition, and the filing of financial statements can indicate significant internal shifts that may affect the company's future performance and stock price.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Heron Therapeutics, Inc. (company) — Registrant
- October 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-33221 (company_id) — Commission File Number
- 94-2875566 (company_id) — I.R.S. Employer Identification No.
- 100 Regency Forest Drive, Suite 300, Cary, NC 27518 (address) — Address of principal executive offices
- AP PHARMA INC /DE/ (company) — Former company name
- ADVANCED POLYMER SYSTEMS INC /DE/ (company) — Former company name
FAQ
What specific changes were made to executive and director compensation arrangements?
The filing indicates updates to compensatory arrangements for certain officers and directors, but the specific details of these changes are not provided in the summary text.
Who are the newly elected directors or appointed officers?
The filing mentions the election of directors and appointment of officers, but their names are not specified in the provided text.
What is the significance of filing financial statements and exhibits with this 8-K?
The financial statements and exhibits likely provide supporting documentation for the corporate governance and compensation changes reported in the 8-K.
When was Heron Therapeutics, Inc. previously known as AP PHARMA INC /DE/ or ADVANCED POLYMER SYSTEMS INC /DE/?
The company changed its name from ADVANCED POLYMER SYSTEMS INC /DE/ on May 11, 1992, and from AP PHARMA INC /DE/ on May 11, 2001.
What is the primary business of Heron Therapeutics, Inc. according to its SIC code?
Heron Therapeutics, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 823 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-10-29 16:05:33
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M
Filing Documents
- hrtx-20251027.htm (8-K) — 59KB
- hrtx-ex99_1.htm (EX-99.1) — 9KB
- 0001193125-25-256300.txt ( ) — 208KB
- hrtx-20251027.xsd (EX-101.SCH) — 50KB
- hrtx-20251027_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 29, 2025, the Company issued a press release with respect to the matters described in this Current Report on Form 8-K. A copy of this press release is attached hereto as Exhibit 99.1. As provided in General Instruction B.2 of Current Report on Form 8-K, the information in this Item 7.01, including Exhibit 99.1, is being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 29, 2025 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: October 29, 2025 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer